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A B S T R A C T
Background. Many patients with congenital heart disease (CHD) acquire rhythm abnormalities related to their
repair, most commonly intraatrial reentrant tachycardia (IART). Treatment of IART in CHD is often multifaceted,
and may include medication, ablation, and pacing. Evidence regarding the use of antitachycardia pacing therapies is
limited.
Objective. The aim of the study is to deﬁne the use and efﬁcacy of antitachycardia pacing in patients with CHD at
a single center.
Results. Eighty implants were performed on 72 patients between 2000 and 2010. Follow-up data of more than 3
months were available for 56 patients; median follow-up time was 2.8 years. Twenty (36%) patients received
successful antitachycardia pacing at a median 1.3 years postimplant. For those patients with IART after implant,
antitachycardia pacing was successful in 57%. Patients with two-ventricle repairs were more likely to have successful
antitachycardia pacing than those with one-ventricle palliation (45% vs. 17%, P = .04). Patients with documented
IART had more successful antitachycardia pacing than those with no documented atrial tachycardia prior to implant
(46% vs. 7%, P = .006). Early complications of antitachycardia pacemaker implant occurred in six patients (11%);
late complications after implant occurred in three patients (5.6%). Of the initial 72 patients implanted, there were
six deaths (8%).
Conclusions. Antitachycardia pacing therapies were successful in the majority of CHD patients who had IART after
implant. Patients without documented atrial tachycardia prior to implant were unlikely to require or receive
successful therapy from antitachycardia pacemaker. Those patients postatrial switch procedure who had documented
IART prior to implant had the highest incidence of successful antitachycardia pacing therapies. Antitachycardia
pacemaker implantation is an adjunct to the management of IART in CHD patients, but may not beneﬁt patients
who have not yet demonstrated IART.
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Introduction
Many patients with congenital heart disease(CHD) acquire rhythm abnormalities
related to their repairs, including atrial tachycar-
dias (ATs), sinus node dysfunction (SND), or com-
plete heart block (CHB). Intraatrial reentrant
tachycardia (IART) is the most common tachycar-
dia mechanism in adults with CHD, particularly
those with complex CHD.1 For those with brady-
cardia pacing indications and IART, there is often
a multifaceted approach to rhythm management,
including medications, ablation, and antitachycar-
dia pacing (ATP).2–4
An antitachycardia pacemaker (ATPM) may be
effective for patients with recurrent IART refrac-
tory to other medical management. Data from a
multicenter study of an earlier ATPM device show
ATP to be effective in terminating atrial arrhyth-
mias in over half of identiﬁed AT episodes without
adverse effects.5 More recently, data on a newer
model ATPM demonstrated successful termina-
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tion of IART in almost half of all episodes, and
suggested that atrial ATP was safe in CHD.6
Limited evidence exists regarding the use and
efﬁcacy of ATP therapies in CHD patients. We
describe our experience with ATPM in a diverse
group of repaired CHD patients to determine
utility and success of ATPM in patients with
CHD.
Methods
All patients with CHD who underwent ATPM
placement between 2000 and 2010 at a single insti-
tution were identiﬁed by query of the clinical
cardiac device database.The objectivewas to deﬁne
the use and efﬁcacy of ATP in patients with CHD.
The Investigational Review Board approved this
study. A retrospective review of medical records
was performed to identify the patients’ congenital
heart malformation and surgical history, history of
IART, successful terminations of IART by the
implanted device or by direct current cardioversion
(DC) cardioversion required after ATPM implan-
tation, and any device complications.
Device data, including AT detection, therapy
data, and complications, were obtained from
device diagnostics or other medical records. Suc-
cessful ATP was deﬁned as successful termination
of IART by any pacing train in the ATP series. If
the initial pacing train did not terminate tachycar-
dia, but additional pacing therapies within the
series did terminate tachycardia, the ATP series
was considered to be successful. ATP was consid-
ered a failure if no pacing train within the ATP
series successfully terminated tachycardia. Com-
plications of device implant were evaluated. Early
complications were deﬁned as those occurring
within 30 days of implant; late complications were
those occurring thereafter.
As many patients were referred to our institu-
tion for device placement but primarily followed
by cardiologists elsewhere, we included only those
patients with follow-up data of more than 3
months in the ﬁnal analysis.
Results
Between 2000 and 2010, 80 implants were per-
formed in 72 patients (Table 1). The median age at
ﬁrst implant was 24.9 years (range 0.5 to 59.6
years).
Bradycardia implant indication was SND in 58
(81%), CHB in 7 (10%), and both SND and CHB
in 2 (3%). There were ﬁve patients (7%) who had
recurrent refractory IART and underwent epicar-
dial pacemaker placement during an otherwise
planned sternotomy with no other documented
bradycardia implant indication.
Initial Implant Data
Single-ventricle patients and those with atrial
switch procedures, including both Mustard and
Senning operations, comprised the majority of the
patient group: 25 (35%) patients had undergone
Fontan palliation; 25 (35%) had undergone atrial
switch procedures. Other two-ventricle repairs
(n = 22; 30%), comprised the remaining patients.
Thirty percent of ATPM patients had a bradycar-
dia pacing indication and no documented IART
before implant, but were felt to be at risk for IART
by implanting physician due to CHD and surgical
history.
Most patients, 64 (94%), had a dual chamber
system. The generator was in all cases designed for
dual chamber functionality, though in some
patients only a functional atrial lead was present,
an off-label use of the device. Epicardial systems
were placed in 29 (42%), endocardial systems in 36
(52%), and 4 patients (6%) had a combination of
epicardial and endocardial leads.
Prior to ATPM implant, 27 (38%) patients were
on antiarrhythmic therapy. Rate control therapy
with beta-blockade or calcium channel blocker
Table 1. Patient Implant Characteristics
n = 72
Age at ATPM implant, median (range) 24.9 years (0.5–59.6)
Gender
Male 44 (61%)
Atrial tachycardia prior to implant 50 (70%)
Congenital heart disease
Single ventricle 25 (35%)
Atrial switch procedure 25 (35%)
Other 22 (30%)
Implant indication
Sinus node disease 58 (81%)
Complete heart block 7 (10%)
SND and CHB 2 (3%)
None 5 (7%)
Dual chamber system 68 (94%)
Ablation/Maze prior to implant 23 (32%)
Antiarrhythmic therapy 27 (38%)
Rate control (BB, CCB) 16 (22%)





Cardioversion prior to implant 23 (32%)
Death 6 (8%)
ATPM, antitachycardia pacemaker; BB, beta-blocker; CCB, calcium channel
blocker; CHB, complete heart block; SND, sinus node disease.
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was used in 16 (22%) patients. Rhythm control
with class I or III antiarrhythmic agents was used
in 24 (33%) patients. Ablation or maze procedure
was performed in 23 (32%) patients prior to
ATPM implant, and 23 (32%) required cardiover-
sion prior to ATPM implant.
There were six deaths (8%), one of which
occurred within 1 month of implant; this patient
was an infant with hypoplastic left heart syndrome
who died while being cannulated for extracorpo-
real membrane oxygenation (ECMO) 24 days
after implant. None of the deaths was related to
device implant or ATP.
Follow-up Antitachycardia Pacing Results
Follow-up data of more than 3 months were avail-
able for 56 patients; median follow-up time was
2.8 years (Table 2). Twenty (36%) patients
received successful ATP. First successful ATP
occurred a median 1.3 years postimplant. More
than 15 successful ATP episodes were documented
in 13 (65%) of the patients who received successful
ATP. For those patients with IART after implant,
ATP was successful in 20 (57%) CHD patients.
DC cardioversion after implant was required in
eight (14%) patients with IART not responsive to
ATP, in contrast to the pre-ATPM implant rate of
32% (P = .02). Four patients who required cardio-
version post-ATPM implant had not had a cardio-
version prior to ATPM implant.
Of the three patients with single-chamber
ATPM included in the follow-up analysis period,
one had AT post-ATPM implantation, for which
ATP was unsuccessful and required cardioversion.
The remaining two patients had no AT docu-
mented postimplant.
Patients with two-ventricle repairs were more
likely to have successful ATP than those with one-
ventricle palliation (45% vs. 17%, P = .04)
(Table 3). Patients with documented IART had
more successful ATP than those with no docu-
mented IART prior to implant (46% vs. 7%, P =
.006). Overall, patients who had undergone atrial
switch procedure had no difference in successful
ATP compared with those after other surgeries
(43% vs. 31%, P = .39). Of those patients with
documented IART prior to ATPM implant,
however, atrial switch patients were more likely to
have successful ATP (67% vs. 28%, P = .01).
Complications
Early complications of ATPM implant occurred in
six patients (11%), including lead failure, lead dis-
lodgement, and excessive redundant lead requiring
revision. Late complications after implant
occurred in three patients (5%), including infec-
tion requiring explant, pocket disruption second-
ary to trauma, and atrial lead failure. ATP was
disabled due to acceleration of the ventricular rate
or 1:1 conduction during ATP to prevent induc-
tion of a ventricular arrhythmia in six patients
(11%).
Discussion
IART is a major source of morbidity in patients
with repaired or palliated CHD, frequently
requiring combination therapy, which may include
antiarrhythmic medications, ablation procedures,
and long-term pacing.7–9 This study reports the
utility and success of ATP in CHD patients. In our
single-center cohort, ATP was successful in the
majority of CHD patients with IART after
implant. Those patients with atrial switch proce-
dures and documented IART prior to implant had
Table 2. Antitachycardia Pacing Results
Follow-up >3 months n = 56
Follow-up, median (range) 2.8 years (0.3–10.7)
AT
Prior to ATPM implant 41 (73%)
Post-ATPM implant 35 (63%)
Antiarrhythmic therapy after implant 29 (52%)
Successful ATP 20 (36%)
AT post-ATPM implant, n = 35 (57%)
Time to first successful ATP, median
(range)
1.3 years (0–6.5)




DC cardioversion required after ATPM
implant
8 (14%)
AT, atrial tachycardia; ATP, antitachycardia pacing; ATPM, antitachycardia
pacemaker.
Table 3. Clinical Factors Associated with Successful Anti-
tachycardia Pacing
Follow-up >3 months n = 56 P
Successful ATP, n = 20 .04
Two-ventricle repair, n = 38 17 (45%)
One-ventricle palliation, n = 18 3 (17%)
Atrial tachycardia prior to implant, n = 41 19 (46%) .006
No atrial tachycardia prior to implant, n = 15 1 (7%)
Atrial switch procedure, n = 21 9 (43%) NS
Other congenital heart surgery, n = 35 11 (31%)
Preimplant AT, successful ATP, n = 19 .01
Atrial switch procedure, n = 12 8 (67%)
Other congenital heart surgery, n = 7 2 (28%)
AT, atrial tachycardia; ATP, antitachycardia pacing.
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the highest incidence of successful ATP therapies.
This study demonstrated a reduction in the need
for cardioversion postimplant. It is important,
however, to note that many patients underwent
concomitant maze procedure/ablation and may
have had medication changes, so direct beneﬁt
from ATP therapy could not be quantiﬁed. The
fact that four patients who had not required car-
dioversion before ATPM implant later required
cardioversion attests to both the evolution of
IART in this population and likely the increased
cardiac surveillance offered by a pacemaker.
The majority of complications related to device
implant were related to lead failure or lead revi-
sion; these data are not signiﬁcantly different from
previously reported incidence of lead revision in
CHD patients.10,11
In a large multicenter prospective study of
patients with anatomically normal hearts and atrial
tachyarrhythmias (AT) including atrial ﬁbrillation,
atrial ﬂutter, and AT, implanted with AT500 and
treated with antiarrhythmic medications, 30% had
no recurrence of AT in the follow-up period, sug-
gesting that atrial pacing alone may serve to
decrease AT.12 It is reasonable to conclude that
CHD patients with SND and IART might also
beneﬁt from atrial pacing; in many of them,
however, their venous connections and cardiac
anatomy make this a technically challenging
option. In this study, patients without documented
IART prior to implant were unlikely to receive
successful therapy from ATP. It seems logical that
ATPM should not be implanted in patients without
documented IART; however, this study did not
evaluate other potential inﬂuences on ATP success.
As implants in CHD patients can be complex, such
as in those with Fontan palliation or atrial switch
procedures, it remains important to consider the
future possibility of IART at an implant principally
for bradycardia. ATPM may still be a reasonable
option at implant if the patient will not be limited
by the few programming constraints of the ATP
device. One important limitation is that pacemaker
leads are not able to be programmed in the unipolar
mode. Thus, the identiﬁcation of those patients
most likely to beneﬁt from ATP remains the most
effective strategy. The devices described in this
study population have largely been supplanted by
newer models, though the ATP programming
options are similar. There remains a cost difference
and level of programming complexity between
ATPMand other bradycardia pacing devices, and it
is important to select the appropriate device for the
individual patient.
ATP programming per se has not been studied
in the CHD population. In a recent analysis of
successful ATP in adults without CHD, ramp
pacing was determined to be more successful than
double-extrastimulus (“Burst +”) pacing13 and may
be considered for further studies in this population
to improve ATP. Additionally, it has been reported
that in patients with tachy-brady syndrome
without CHD, initial ramp ATP was successful in
most patients who had successful ATP.14 This
series represents no uniform strategy for atrial
ATP programming, which should be further
investigated in CHD patients.
Conclusion
ATP is an effective component in the multifaceted
management of IART in postsurgical CHD, and
spared numerous DC cardioversions in this series.
Patients without documented IART prior to
implant, however, were unlikely to receive success-
ful therapy from ATPM systems. ATP therapies
were most successful in patients with two-ventricle
repairs, speciﬁcally atrial switch procedures with
documented IART prior to implant.
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